Cargando…

Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review

Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, Darryl P., Cirne, Filipe, Aghel, Nazanin, Baro Vila, Rocio C., Cavalli, Germano D., Ellis, Peter M., Healey, Jeff S., Whitlock, Richard, Khalaf, Dina, Mian, Hira, Jolly, Sanjit S., Mehta, Shamir R., Dent, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443114/
https://www.ncbi.nlm.nih.gov/pubmed/37614581
http://dx.doi.org/10.1016/j.jaccao.2023.05.008
_version_ 1785093753205161984
author Leong, Darryl P.
Cirne, Filipe
Aghel, Nazanin
Baro Vila, Rocio C.
Cavalli, Germano D.
Ellis, Peter M.
Healey, Jeff S.
Whitlock, Richard
Khalaf, Dina
Mian, Hira
Jolly, Sanjit S.
Mehta, Shamir R.
Dent, Susan
author_facet Leong, Darryl P.
Cirne, Filipe
Aghel, Nazanin
Baro Vila, Rocio C.
Cavalli, Germano D.
Ellis, Peter M.
Healey, Jeff S.
Whitlock, Richard
Khalaf, Dina
Mian, Hira
Jolly, Sanjit S.
Mehta, Shamir R.
Dent, Susan
author_sort Leong, Darryl P.
collection PubMed
description Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer.
format Online
Article
Text
id pubmed-10443114
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104431142023-08-23 Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review Leong, Darryl P. Cirne, Filipe Aghel, Nazanin Baro Vila, Rocio C. Cavalli, Germano D. Ellis, Peter M. Healey, Jeff S. Whitlock, Richard Khalaf, Dina Mian, Hira Jolly, Sanjit S. Mehta, Shamir R. Dent, Susan JACC CardioOncol State-of-the-Art Review Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer. Elsevier 2023-07-11 /pmc/articles/PMC10443114/ /pubmed/37614581 http://dx.doi.org/10.1016/j.jaccao.2023.05.008 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle State-of-the-Art Review
Leong, Darryl P.
Cirne, Filipe
Aghel, Nazanin
Baro Vila, Rocio C.
Cavalli, Germano D.
Ellis, Peter M.
Healey, Jeff S.
Whitlock, Richard
Khalaf, Dina
Mian, Hira
Jolly, Sanjit S.
Mehta, Shamir R.
Dent, Susan
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_full Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_fullStr Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_full_unstemmed Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_short Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_sort cardiac interventions in patients with active, advanced solid and hematologic malignancies: jacc: cardiooncology state-of-the-art review
topic State-of-the-Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443114/
https://www.ncbi.nlm.nih.gov/pubmed/37614581
http://dx.doi.org/10.1016/j.jaccao.2023.05.008
work_keys_str_mv AT leongdarrylp cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT cirnefilipe cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT aghelnazanin cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT barovilarocioc cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT cavalligermanod cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT ellispeterm cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT healeyjeffs cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT whitlockrichard cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT khalafdina cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT mianhira cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT jollysanjits cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT mehtashamirr cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview
AT dentsusan cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview